City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference (RNAi) therapies headed by a ...

Although real progress has been made in managing depression over recent decades, significant hurdles remain. In fact, around ...

The EMA's human medicines committee, the CHMP, has recommended approval of Eli Lilly's oral GLP-1 agonist Foundayo for weight ...

"Treating thyroid eye disease requires balancing efficacy, safety, and the practical realities of long-term treatment," said ...

The CHMP has backed Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least ...

AstraZeneca has agreed to pay insitro $40 million upfront to use the latter's AI-powered drug discovery platform to find new ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results with a ...

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure from US President Donald Trump. The company has indicated that it is ...

Shares in Abivax were tracking up this morning as a media report in France suggested a takeover by Eli Lilly – worth €15 billion ($17.5 billion) – could be on the cards. French newspaper La Lettre ...

Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, has announced the successful closing of an $11.6 ...

NICE has said that four artificial intelligence technologies can be deployed by the NHS to detect fractures on X-rays in urgent care, while more evidence on their value is generated, but has limited ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock was ...